Page 110 - ITPS-7-2

INNOSC Theranostics and
Pharmacological Sciences Molecular docking against SARS-CoV-2

32. Okamoto M, Toyama M, Baba M. The chemokine receptor 43. Parienti JJ, Prazuck T, Peyro-Saint-Paul L, et al. Effect
antagonist cenicriviroc inhibits the replication of SARS- of tenofovir disoproxil fumarate and emtricitabine on
CoV-2 in vitro. Antiviral Res. 2020;182:104902. nasopharyngeal SARS-CoV-2 viral load burden amongst
doi: 10.1016/J.ANTIVIRAL.2020.104902 outpatients with COVID-19: A pilot, randomized, open-
label phase 2 trial. EClinicalMedicine. 2021;38:100993.
33. García-Lledó A, Gómez-Pavón J, del Castillo JG, et al.
Pharmacological treatment of COVID-19: An opinion doi: 10.1016/j.eclinm.2021.100993
paper. Rev Esp Quimioter. 2021;35(2):115-130. 44. Montejano R, de la Calle-Prieto F, Velasco M, et al.
doi: 10.37201/req/158.2021 Tenofovir disoproxil fumarate/emtricitabine and baricitinib
for patients at high risk of severe coronavirus disease 2019:
34. Vellingiri B, Jayaramayya K, Iyer M, et al. COVID-19: The PANCOVID randomized clinical trial. Clin Infect Dis.
A promising cure for the global panic. Sci Total Environ. 2022;76(3):e116-e125.
2020;725:138277.
doi: 10.1093/cid/ciac628
doi: 10.1016/j.scitotenv.2020.138277
45. Rossignol JF, Bardin MC, Fulgencio J, Mogelnicki D,
35. Gidari A, Sabbatini S, Pallotto C, et al. Nelfinavir: An old ally Bréchot C. A randomized double-blind placebo-controlled
in the COVID-19 fight? Microorganisms. 2022;10(12):2471. clinical trial of nitazoxanide for treatment of mild or
doi: 10.3390/microorganisms10122471 moderate COVID-19. EClinicalMedicine. 2022;45:101310.
36. Uraki R, Ito M, Kiso M, et al. Efficacy of antivirals and doi: 10.1016/j.eclinm.2022.101310
bivalent mRNA vaccines against SARS-CoV-2 isolate 46. Zhai MZ, Lye CT, Kesselheim AS. Need for transparency
CH1.1. Lancet Infect Dis. 2023;23:522-526. and reliable evidence in emergency use authorizations for
doi: 10.1016/S1473-3099(23)00132-9 coronavirus disease 2019 (COVID-19) therapies. JAMA
Intern Med. 2020;180(9):1145-1146.
37. Rezkikov LR, Norris MH, Vashisht R, et al. Identification
of antiviral antihistamines for COVID-19 repurposing. doi: 10.1001/jamainternmed.2020.2402
Biochem Biophys Res Commun. 2021;29:173-179. 47. Geetanjali S, Srivastava R, Singh R. Synthesis of four
doi: 10.1016/j.bbrc.2020.11.095 heterocyclic drug molecules repurposed for COVID-19.
Mini Rev Org Chem. 2022;19(2):180-187.
38. Basha SH. Coronavirus drugs-a brief overview of past,
present and future. J PeerSci. 2020;2(2):e1000013. doi: 10.2174/1570193X18666210325121225
39. Meini S, Pagotto A, Longo B, Vendramin I, Pecori D, Tascini C. 48. Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the
Role of Lopinavir/Ritonavir in the treatment of Covid-19: treatment of COVID-19. Int J Infect Dis. 2021;102:501-508.
A review of current evidence, guideline recommendations, doi: 10.1016/j.ijid.2020.10.069
and perspectives. J Clin Med. 2020;9(7):2050.
49. Rabie AM. Efficacious preclinical repurposing of the nucleoside
doi: 10.3390/jcm9072050 analogue didanosine against COVID-19 polymerase and
40. Burastero GJ, Orlando G, Santoro A, et al. Ceftazidime/ exonuclease. ACS Omega. 2022;7:21385-21396.
Avibactam in ventilator-associated pneumonia due to doi: 10.1021/acsomega.1c07095
difficult-to-treat non-fermenter gram-negative bacteria in
Covid-19 patients: A case series and review of the literature. 50. Cento V, Perno CF. Dolutegravir plus lamivudine two-drug
Antibiotics (Basel). 2022;11(8):1007. regimen: Safety, efficacy and diagnostic considerations for
its use in real-life clinical practice-a refined approach in the
doi: 10.3390/antibiotics11081007
COVID-19 era. Diagnostics (Basel). 2021;11(5):809.
41. Nourian A, Khalili H, Ahmadinejad Z, et al. Efficacy and doi: 10.3390/diagnostics11050809
safety of sofosbuvir/ledipasvir in treatment of patients
with COVID-19; A randomized clinical trial. Acta Biomed. 51. Heidary F, Madani S, Gharebaghi R, Asadi-Amoli F.
2021;91(4):e2020102. Acyclovir as a potential add-on therapy in COVID-19
treatment regimes. Pharm Sci. 2021;27(Suppl 1):S68-S77.
doi: 10.23750/abm.v91i4.10877
doi: 10.34172/PS.2021.38
42. Czarnogorski M, Benn P, McCoig C, et al. Brief report: Impact
of COVID-19 on Cabotegravir plus Rilpivirine long-acting 52. Meng M, Zhang S, Dong X, et al. COVID-19 associated EBV
dosing across 6 ongoing global phase IIb and III clinical reactivation and effects of ganciclovir treatment. Immun
trials. J Acquir Immune Defic Syndr. 2022;91(2):157-161. Inflamm Dis. 2022;10(4):e597.
doi: 10.1097/QAI.0000000000003031 doi: 10.1002/iid3.597

Volume 7 Issue 2 (2024) 7 doi: 10.36922/itps.1651